Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 27, 2026
TickeronGET DAILY SIGNALS
FIGS Stock: Can It Climb to $20? Assessing the +110% Upside Case

FIGS Stock: Can It Climb to $20? Assessing the +110% Upside Case

Key Takeaways

  • Price Target: $20 per share — a level not yet reached in FIGS's current cycle and representing roughly 110% upside from recent prices around $9.50.
  • Strongest Bullish Factors: Accelerating revenue growth (28% in Q1 2026), international expansion gaining traction, active customers surpassing 3 million, and a debt-free balance sheet with $277 million in net cash.
  • Biggest Risks: Tariff pressures on sourcing costs, freight headwinds, margin recovery still in progress, and the stock's elevated valuation even after the recent pullback.
  • Key Technical Levels: The $8–$10 zone serves as a critical support area; a sustained move above the 200-day moving average near $12.79 would signal recovering momentum toward prior resistance near $15–$17.
  • Bottom Line: Reaching $20 is plausible over a multi-year horizon if international expansion and margin recovery accelerate, but the near-term path is challenged by tariff uncertainty and the stock's recent loss of momentum.

Why Investors Are Watching the $20 Level

FIGS, Inc., the direct-to-consumer healthcare apparel company, has experienced a dramatic round-trip over the past year. After trading below $4 in early 2025, the stock staged a powerful recovery, surging above $17 by March 2026 behind strong earnings and a flurry of analyst upgrades. Since that peak, however, shares have retreated sharply, settling near $9.50 as of late July 2026. The question now confronting investors is whether the growth story can regain enough momentum to push the stock toward $20 — a psychologically significant level that would represent new highs for this cycle and align with the most bullish Wall Street targets.

Company Overview

Founded in 2013 by Heather Hasson and Trina Spear, FIGS disrupted the staid medical uniform industry by designing premium scrubs and healthcare apparel with the fit, feel, and branding sensibility of athleisure. The company went public in May 2021 at $22 per share and briefly traded above $50 during the pandemic-era surge in healthcare spending. Today, FIGS generates trailing twelve-month revenue of approximately $666 million, serves over 3 million active customers, and operates across North America, Europe, Asia Pacific, and the Middle East through its e-commerce platform and a growing network of physical retail locations.

What Could Drive the Next Leg Higher

Several catalysts could support a move toward $20. First, international expansion is delivering tangible results — international sales grew approximately 50% year-over-year in the most recent quarter. The company's TEAMS platform, which serves healthcare institutions through bulk purchasing, represents a largely untapped B2B opportunity. Management raised full-year 2026 revenue growth guidance to 14%–16% following Q1 results that delivered $159.9 million in revenue, a 28% increase from the prior year. The company's balance sheet remains a source of strength, with $277 million in net cash and no long-term debt, providing ample flexibility for share buybacks and strategic investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Wall Street has taken notice. Oppenheimer carries a $22 price target with an Outperform rating, while BTIG maintains a Buy rating with a $20 target. KeyBanc's Overweight rating and $19 target reflect confidence that the company's "growth algorithm remains intact," citing healthy customer engagement trends and limited resistance to recent pricing actions.

What Could Prevent the Move

Tariffs remain the most significant obstacle. Section 122 tariffs, currently at 10% and potentially rising to 15%, directly pressure gross margins on imported goods. Management acknowledged that freight cost headwinds and the pause of a duty drawback program will create an uneven margin cadence throughout 2026. While Q1 gross margin improved modestly to 67.7%, the full-year outlook assumes only slight improvement over 2025's 66.5%.

Competition also deserves attention. The healthcare apparel market, while historically fragmented, is attracting attention from larger players. Lower-priced alternatives continue to test FIGS's premium positioning, and the company must demonstrate that its brand strength can sustain pricing power without relying on promotions that erode profitability.

Technical Levels That Matter

The stock's technical picture presents a mixed outlook. After peaking at $17.48 in early March 2026, shares have fallen below both the 50-day moving average near $12.69 and the 200-day moving average near $12.79 — a configuration that typically signals bearish momentum. The $9–$10 zone represents an important support area; a breakdown below this range could expose the stock to the mid-$7 area, where Goldman Sachs's prior price target sat before its February upgrade. On the upside, reclaiming the $12–$13 region would be a necessary first step toward rebuilding confidence, with the prior peak near $17 serving as the next major resistance zone before $20 becomes a realistic discussion. From what I see, monitoring these levels closely helps frame the risk-reward picture.

Analyst Opinions and Price Targets

The analyst community holds a Moderate Buy consensus on FIGS, with an average 12-month price target near $15.93, according to MarketBeat data from 11 covering analysts. However, targets span a wide range — from a bearish $7.50 to a bullish $22.00 — reflecting genuine disagreement about the company's trajectory. The clustering of targets between $15 and $20 suggests that even bullish analysts are tempering enthusiasm with caution around margin recovery and valuation. Notably, the average target represents approximately 56% upside from current levels but still falls meaningfully short of $20, underscoring that the $20 objective requires execution beyond the consensus base case.

Valuation Perspective

Even after its recent decline, FIGS trades at a trailing P/E ratio above 40 — a premium multiple that leaves little room for disappointment. The forward P/E near 34 suggests the market expects significant earnings growth to materialize. For the stock to reach $20 without multiple expansion, EPS would need to roughly double from current levels. With FY2026 consensus EPS estimates around $0.25–$0.27 and FY2027 projections near $0.35, reaching $20 would likely require maintaining an elevated growth multiple while delivering consistent earnings beats — a demanding but not impossible combination.

Final Assessment

The path to $20 for FIGS stock is plausible but conditional. The company's revenue growth trajectory, international momentum, fortress balance sheet, and growing customer base provide a credible foundation. However, the near-term reality includes tariff headwinds, margin uncertainty, and a stock that has lost technical momentum. Reaching $20 would likely require multiple catalysts to align: successful mitigation of tariff impacts, sustained margin expansion, accelerating international contribution, and a broader market environment supportive of growth-at-a-reasonable-price narratives. Investors should monitor the upcoming Q2 earnings report in early August 2026 for updated guidance on margins, tariff assumptions, and progress on international initiatives — these will be critical signposts on the road to $20.

Using Tickeron’s AI Daily Buy/Sell Signals in My Process

Navigating a stock with as much volatility as FIGS requires timely, data-driven insight. In my own analysis, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor shifting conditions across thousands of stocks and ETFs. The platform’s AI evaluates technical patterns and fundamentals to generate Buy, Sell, or Hold signals, helping me stay ahead of potential trend changes without replacing my own due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FIGS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


FIGS's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for FIGS moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 30 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for FIGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 32 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FIGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

FIGS broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on FIGS as a result. In 73 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

Following a +8.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where FIGS advanced for three days, in 206 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 177 of 218 cases where FIGS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. FIGS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 57 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FIGS's P/B Ratio (7.444) is slightly higher than the industry average of (2.911). FIGS has a moderately high P/E Ratio (52.158) as compared to the industry average of (14.016). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.686). Dividend Yield (0.000) settles around the average of (0.328) among similar stocks. FIGS's P/S Ratio (3.461) is very high in comparison to the industry average of (0.827).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FIGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are VF Corp (NYSE:VFC), G-III Apparel Group Ltd (NASDAQ:GIII), Canada Goose Holdings (NYSE:GOOS), Lakeland Industries (NASDAQ:LAKE).

Industry description

Apparel/footwear might be slightly more ‘cyclical’ in the largely non-cyclical category of non-durables. While digital giants like Amazon have been rapidly expanding their presence, traditional clothing/footwear retailers have also been bulking up their online presence in recent years, to milk the burgeoning trend of online shopping among consumers across the globe. The apparel and footwear retail market was valued at around $ 360 billion in 2018, and this figure was expected to reach about $386 billion by 2020 (according to a Statista report). NIKE, Inc, V.F. Corporation and Under Armour, Inc. are some of the companies with the largest U.S. stock market caps in this segment.

Market Cap

The average market capitalization across the Apparel/Footwear Industry is 3.03B. The market cap for tickers in the group ranges from 1.66K to 25.98B. HMRZF holds the highest valuation in this group at 25.98B. The lowest valued company is SQBGQ at 1.66K.

High and low price notable news

The average weekly price growth across all stocks in the Apparel/Footwear Industry was -7%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 1%. JXG experienced the highest price growth at 11%, while NCI experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Apparel/Footwear Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was 51% and the average quarterly volume growth was 49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 45
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: 7 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ApparelFootwear

Industry
N/A
Address
2834 Colorado Avenue
Phone
+1 424 300-8330
Employees
388
Web
https://www.wearfigs.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.